Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AnaptysBio Inc (ANAB)
NASDAQ:ANAB
Holding ANAB?
Track your performance easily
ANAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.36 - $41.31
Previous Close$21.31
Volume416.11K
Average Volume (3M)399.06K
Market Cap
$653.91M
Enterprise Value$240.29M
Total Cash (Recent Filing)$430.12M
Total Debt (Recent Filing)$16.49M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Feb 27, 2025EPS Estimate
-$1.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.07
Shares Outstanding30,428,682
10 Day Avg. Volume819,576
30 Day Avg. Volume399,061
Standard Deviation0.21
R-Squared0.00337
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)7.69
Price to Sales (P/S)11.44
Price to Cash Flow (P/CF)-16.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.20
Enterprise Value/Gross Profit14.01
Enterprise Value/Ebitda-1.58
Forecast
1Y Price Target
$51.50Price Target Upside141.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
AnaptysBio News
Bulls Say, Bears Say
Bulls Say
Clinical Trials And PotentialANB032 could unlock meaningful upside for ANAB shares if successful.
Financial ValuationANAB shares are significantly undervalued, since it has three I&I clinical-stage assets and a fourth which should enter the clinic early next year.
Pipeline ProgressANAB continues to progress all four pipeline programs on schedule.
Bears Say
Analyst ConfidenceANB032 program receives little credit in the stock, and analysts maintain relatively low confidence in the upcoming topline data.
Drug Development ChallengesInvestors will likely assign a lower probability of success for rosnilimab's Phase 2 trial for rheumatoid arthritis.
Market PressureShares are trading down significantly as LLY has removed peresolimab from its pipeline, raising concerns about similar drugs like rosnilimab.
---
Ownership Overview
43.40% Insiders
20.20% Mutual Funds
2.86% Other Institutional Investors
22.01% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANAB FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest stock price was $13.36 and its highest was $41.31 in the past 12 months.
What is AnaptysBio Inc’s market cap?
Currently, no data Available
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is Feb 27, 2025 which is in 109 days.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on Nov 05, 2024. The company reported -$1.14 earnings per share for the quarter, beating the consensus estimate of -$1.647 by $0.507.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is -$1.56.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 30,428,682 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of -$1.14 in its last earnings report, beating expectations of -$1.647. Following the earnings report the stock price went up 11.72%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Among the largest hedge funds holding AnaptysBio Inc’s share is Woodline Partners LP. It holds AnaptysBio Inc’s shares valued at 6M.
---
AnaptysBio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.50 (141.67% Upside)
$51.50 (141.67% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 572.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $10.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 22.5%
Last 30 Days ▲ 26.0%
Last 30 Days ▲ 26.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.48%
12-Months-Change
Fundamentals
Return on Equity
-161.81%
Trailing 12-Months
Asset Growth
1.25%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
---
ANAB Stock 12 Month Forecast
Average Price Target
$51.50
▲(141.67% Upside)
Technical Analysis
Best Analysts Covering ANAB
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
-32.74%
reiterated a buy rating 2 months ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of -32.74% per trade.
---